Marshall Wace LLP Buys Shares of 101,899 Protalix BioTherapeutics, Inc. (NYSE:PLX)

Marshall Wace LLP bought a new position in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 101,899 shares of the company's stock, valued at approximately $192,000. Marshall Wace LLP owned approximately 0.14% of Protalix BioTherapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new position in Protalix BioTherapeutics in the fourth quarter valued at $35,000. PFG Investments LLC acquired a new position in Protalix BioTherapeutics in the fourth quarter valued at $39,000. Virtu Financial LLC acquired a new position in Protalix BioTherapeutics in the third quarter valued at $44,000. Prudential Financial Inc. acquired a new position in Protalix BioTherapeutics in the fourth quarter valued at $68,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Protalix BioTherapeutics by 17.0% during the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company's stock worth $2,102,000 after buying an additional 162,100 shares during the period. Institutional investors and hedge funds own 16.53% of the company's stock.

Analyst Ratings Changes

PLX has been the subject of several recent research reports. StockNews.com downgraded shares of Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 20th. HC Wainwright increased their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Trading Down 40.5%

Shares of PLX traded down $1.17 during mid-day trading on Friday, hitting $1.72. 5,945,414 shares of the company's stock were exchanged, compared to its average volume of 493,464. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.82 and a fifty-two week high of $3.10. The firm has a market capitalization of $136.77 million, a P/E ratio of -13.23 and a beta of -0.05. The business's 50 day moving average is $2.54 and its two-hundred day moving average is $2.16.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. On average, equities research analysts forecast that Protalix BioTherapeutics, Inc. will post 0.01 earnings per share for the current year.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.